Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
LONDON, 12 July 2007 - Cancer drug developer Antisoma plc (LSE: ASM, US OTC: ATSMY) today announces new data from its phase II trial of ASA404 in recurrent, platinum-sensitive ovarian cancer. This trial compares patients receiving ASA404 plus chemotherapy (n=37) with patients receiving chemotherap...New Report Just Published: World Prostate Cancer Therapeutics Market Report
...in Prostate Cancer II-53 Isis and OncoGenex Reveals Positive results of OGX-011 Molecule in HRPC II-53 Antisoma Completes Phase 2 Study of asa404 in Prostate Cancer II-53 Cougar Conducts Phase I/II Clinical Trials on CB7630 in Patients with Prostate Cancer II-54 Ambrilia Unveils Resu...Vadimezan - Wikipedia, the free encyclopedia
Vadimezan or ASA404 is a tumor-vascular disrupting agent (tumor-VDA) that attacks the blood supply of a cancerous tumor to cause tumor regression.Novartis Oncology Research: ASA404 For Lung Cancer
Read information about ASA404, a Novartis Oncology investigational cancer treatment that disrupts established tumor vasculature, inhibiting tumor blood flow and ...ASA404 Vascular Disrupting Agent for Solid Tumours - Drug Development ...
Project on the ASA404 vascular disrupting agent for solid tumours by Antisoma and Novartis. ... Novartis subsequently acquired worldwide rights to ASA404 in 2007. ...Positive data on Antisoma's ASA404 presented at ASCO | Reuters
LONDON, UK, Jun 01 (MARKET WIRE) -- London, UK, and Chicago, IL, 1 June 2008 - Antisoma (LSE: ASM; USOTC:ATSMY) announces that two presentations supporting ASA404 ...starting a Phase III trial for the drug, ASA404
ASA404 ... Novel mechanism of action of ASA404 disrupts existing blood supply to tumors ... ASA404 is one of six novel oncology compounds Novartis is developing for ...ATTRACT Clinical Trial – Antivascular Targeted Therapy: Researching ...
Learn about ATTRACT clinical trial from Novartis Oncology, and investigational cancer treatment: Antivascular Targeted Therapy: Researching ASA404 in Cancer Treatment.